Log in to save to my catalogue

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder...

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9197524

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

About this item

Full title

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

Publisher

United States: American Society for Clinical Investigation

Journal title

The Journal of clinical investigation, 2022-06, Vol.132 (12), p.1-17

Language

English

Formats

Publication information

Publisher

United States: American Society for Clinical Investigation

More information

Scope and Contents

Contents

Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladder tumors, and samples from co...

Alternative Titles

Full title

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9197524

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9197524

Other Identifiers

ISSN

1558-8238,0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI145666

How to access this item